Oscotec Inc.

Translating science into medicine
Sign Up
List of Articles
Date Website Media Pipeline
2019-12-14 Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC Targeted Oncology Lazertinib
2019-11-04 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study THE LANCET ONCOLOGY Lazertinib
2018-11-05 Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech BusinessKorea Lazertinib
2020-05-18 Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations BioSpace Lazertinib
2007-02-20 IPOs spawn instant billionaires The Korea Herald Oscotec
2016-08-23 INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs Scrip (Informa Pharma Intelligence) Oscotec
2018-05-16 Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018 Businesswire Lazertinib
2019-01-28 Genosco gears up for IPO THE INVESTOR Genosco
2014-04-03 G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. PubMed SKI-G-801
2019-11-04 AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications Molecular Cancer SKI-G-801
2019-07-01 Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models CANCER RESEARCH SKI-G-801
2019-12-02 "Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan" PRNewswire Genosco
Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.